

Curriculum Vitae

Personal Information:

- Forename: Ali
- Surname: Jahanian-Najafabadi
- Date and Place of Birth: 1982- Najafabad, Isfahan.
- Languages: Persian (Native), English (Fluent), German, French (Elementary)



Contact Information:

- Present Address: Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences and Health Services, Hezar Jarib Ave. Isfahan, Iran.
- Tel: +98 313 7927056
- Fax: +98 313 6680011
- Email: jahanian@pharm.mui.ac.ir; ajnajafabadi@yahoo.com

Education and trainings:

- Nov 2018-Sep 2019: Sabbatical leave at University of Waterloo, Waterloo, ON. Canada
- 2006- 2012: Ph.D. of Pharmaceutical Biotechnology, Pasteur Institute of Iran, Tehran, Iran.
- 2000-2006: Doctor of Pharmacy (Pharm. D.), School of Pharmacy, Isfahan University of Medical Sciences and Health Services, Isfahan, Iran.
- **Ph. D. Thesis**
 - **Expression of A1-GMCSF fusion protein in Baculovirus expression system for biotherapy of hematologic malignancies.** Supervisors: Saeid Bouzari (Ph.D.), Mana Oloomi (Ph.D.)

Pharm. D. Thesis:

- **Cloning of Polyhydroxyalkanoate Synthase Genes of *Pseudomonas aeruginosa* PTCC 1310.** Supervisors: Daryoush Abedi (Ph.D), Hamid Mir Mohammad Sadeghi (Ph.D), Sadegh Valian Boroujeni (Ph.D).

▪ Selected Papers:

1. Mitochondrial transplantation ameliorates ischemia/reperfusion-induced kidney injury in rat. Hanieh Jabbari, Amaneh Mohammadi Roushandeh, Mojdeh Kheirandish Rostami, Mohammad Taghi Razavi-Toosi, Mohammad Ali Shokrgozar, **Ali Jahanian-Najafabadi**, Yoshikazu Kuwahara, Mehryar Habibi Roudkenar. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease*. Volume 1866, Issue 8, 1 August 2020, 165809
2. RGD peptide grafted polybutylene adipate-co-terephthalate/gelatin electrospun nanofibers loaded with a matrix metalloproteinase inhibitor drug for alleviating of wounds: an in vitro/in vivo study. Jaleh Varshosaz, Khatereh Arabloo, Nasim Sarrami, Erfaneh Ghassami, Emadeddin Yazdani Kachouei, Monireh Kouhi & **Ali Jahanian-Najafabadi**. *Drug Development and Industrial Pharmacy*.46 (3), 3 March 2020, Pages 484-497
3. Implication and role of neutrophil gelatinase-associated lipocalin in cancer: lipocalin-2 as a potential novel emerging comprehensive therapeutic target for a variety of cancer types. Sina Rahimi, Amaneh Mohammadi Roushandeh, Ebrahim Ahmadzadeh, **Ali Jahanian-Najafabadi** & Mehryar Habibi Roudkenar. *Mol Biol Rep* 47, 2327–2346 (2020).
4. Mitochondrial characteristics contribute to proliferation and migration potency of MDA-MB-231 cancer cells and their response to cisplatin treatment. Mojdeh Kheirandish-Rostami, Mehryar Habibi Roudkenar, **Ali Jahanian-Najafabadi**, Kazuo Tomita, Yoshikazu Kuwahara, Tomoaki Sato, Amaneh Mohammadi Roushandeh. *Life Sciences*, 244, 1 March 2020, 117339
5. Expression and one step intein-mediated purification of biologically active human G-CSF in *Escherichia coli*. Sima, S., Shafiee, F., **Jahanian-Najafabadi, A.** *Mol Biol Rep* 47, 2861–2869 (2020)
6. Design and production of new chimeric reteplase with enhanced fibrin affinity: a theoretical and experimental study. Mohammadi, E., Mahnam, K., **Jahanian-Najafabadi, A.**, Sadeghi, H.M.M. *Journal of Biomolecular Structure and Dynamics*, 2020.

7. Targeted Diphtheria Toxin-Based Therapy: A Review Article. Shafiee, F., Aucoin, M.G., **Jahanian-Najafabadi, A.** *Frontiers in Microbiology*. 10: 18 October 2019, Article number 2340
8. Production of Novel Camelid Anti-CXCL10 Specific Polyclonal Antibodies and Evaluation of Their Bioreactivity. Sadeghian-Rizi, T, Behdani, M, Khanahmad, H, Ghasemi-Dehkordi, P, Mirmohammad Sadeghi, H, **Jahanian-Najafabadi, A.** *International Journal of Peptide Research and Therapeutics*. Volume 25, Issue 2, 1 June 2019, Pages 535-540.
9. HER-2 aptamer-targeted Ecoflex® nanoparticles loaded with docetaxel promote breast cancer cells apoptosis and anti-metastatic effect. Ghassami E, Varshosaz J, Mirian M, **Jahanian-Najafabadi A.** *IET Nanobiotechnol.* 2019; 13(4):428-434.
10. A Bi-Functional Targeted P28-NRC Chimeric Protein with Enhanced Cytotoxic Effects on Breast Cancer Cell Lines. Soleimani, M Sadeghi, HM; **Jahanian-Najafabadi, A.** *Iran J Pharm Res.* 2019 Spring: 18(2): 735-744
11. High-yield Production of Granulocyte-macrophage Colony-stimulating Factor in *E. coli* BL21 (DE3) By an Auto-induction Strategy. Malekian R, **Jahanian-Najafabadi A,** Moazen F, Ghavimi R, Mohammadi E, Akbari V. *Iran J Pharm Res.* 2019 Winter;18(1):469-478.
12. Improvement of soluble expression of GM-CSF in the cytoplasm of *Escherichia coli* using chemical and molecular chaperones. Malekian R, Sima S, **Jahanian-Najafabadi A,** Moazen F, Akbari V. *Protein Expr Purif.* 2019; 160:66-72.
13. Generation and Characterization of a Functional Nanobody against Inflammatory Chemokine CXCL10, as a Novel Strategy for the Treatment of Multiple Sclerosis. Sadeghian-Rizi T, Behdani M, Khanahmad H, Sadeghi HM, **Jahanian-Najafabadi A.** *CNS Neurol Disord Drug Targets.* 2019;18(2):141-148.
14. Preparation and Characterization of Spray-Dried Inhalable Powders Containing Polymeric Micelles for Pulmonary Delivery of Paclitaxel in Lung Cancer. Rezazadeh M, Davatsaz Z, Emami J, Hasanzadeh F, **Jahanian-Najafabadi A.** *J Pharm Pharm Sci.* 2018;21(1s):200s-214s.
15. Chronic Oral Arsenic Exposure and Its Correlation with Serum S100B Concentration. Golmohammadi J, **Jahanian-Najafabadi A,** Aliomrani M. *Biol Trace Elem Res.* 2019 May;189(1):172-179.
16. A-NGR fusion protein induces apoptosis in human cancer cells. Mohammadi-Farsani A, Habibi-Roudkenar M, Golkar M, Shokrgozar MA, **Jahanian-Najafabadi A,** KhanAhmad H, Valiyari S, Bouzari S. *EXCLI J.* 2018 Jun 25;17:590-597.
17. Efavirenz oral delivery via lipid nanocapsules: formulation, optimisation, and ex-vivo gut permeation study. Varshosaz J, Taymouri S, **Jahanian-Najafabadi A,** Alizadeh A. *IET Nanobiotechnol.* 2018 Sep;12(6):795-806.

- Therapeutic Targeting of Chemokines and Chemokine Receptors in Multiple Sclerosis: Opportunities and Challenges. Sadeghian-Rizi T, Khanahmad H, **Jahanian-Najafabadi A**. *CNS Neurol Disord Drug Targets*. 2018;17(7):496-508.
18. Lipocalin2 Protects Human Embryonic Kidney Cells against Cisplatin-Induced Genotoxicity. Sadeghi F, Etebari M, Habibi Roudkenar M, **Jahanian-Najafabadi A**. *Iran J Pharm Res*. 2018 Winter;17(1):147-154.
 19. Pharmacokinetics and in vitro/in vivo antitumor efficacy of aptamer-targeted Ecoflex® nanoparticles for docetaxel delivery in ovarian cancer. Ghassami E, Varshosaz J, **Jahanian-Najafabadi A**, Minaiyan M, Rajabi P, Hayati E. *Int J Nanomedicine*. 2018 Jan 23;13:493-504.
 20. Enhanced solubility, oral bioavailability and anti-osteoporotic effects of raloxifene HCl in ovariectomized rats by Igepal CO-890 nanomicelles. Varshosaz J, Ziaei V, Minaiyan M, **Jahanian-Najafabadi A**, Sayed-Tabatabaei L. *Pharm Dev Technol*. 2019 Feb;24(2):133-144.
 21. A novel mixed polymeric micelle for co-delivery of paclitaxel and retinoic acid and overcoming multidrug resistance: synthesis, characterization, cytotoxicity, and pharmacokinetic evaluation. Emami J, Rezazadeh M, Mashayekhi M, Rostami M, **Jahanian-Najafabadi A**. *Drug Dev Ind Pharm*. 2018 May;44(5):729-740.
 22. Transferrin-targeted poly(butylene adipate)/terephthalate nanoparticles for targeted delivery of 5-fluorouracil in HT29 colorectal cancer cell line. Varshosaz, J. Riahi, S. Ghassami, E. **Jahanian-Najafabadi, A**. *Journal of Bioactive and Compatible Polymers*. Volume 32, Issue 5, 1 September 2017, Pages 503-527
 23. Cloning, Expression, and Assessment of Cytotoxic Effects of A-NGR Fusion Protein. Mohammadi-Farsani, A. **Jahanian-Najafabadi, A**. Habibi-Roudkenar, M. Golkar, M. Shokrgozar, M.A. KhanAhmad, H. Golshani, M. Valiyari, S. Bouzari, S. *International Journal of Peptide Research and Therapeutics*. 14 August 2017, Pages 1-7
 24. In-vivo evaluation of DT386-BR2, a promising anticancer fusion protein, in mice model. Shafiee, F. Enteshari, R. Rabbani, M. **Jahanian-Najafabadi, A**. *Journal of Isfahan Medical School*. Volume 35, Issue 433, August 2017, Pages 655-661
 25. Lipocalin 2 enhances mesenchymal stem cell-based cell therapy in acute kidney injury rat model. Roudkenar, M.H. Halabian, R. Tehrani, H.A. Amiri, F. **Jahanian-Najafabadi, A**. Roushandeh, A.M. Abbasi-Malati, Z. Kuwahara, Y. *Cytotechnology*. 2 June 2017, Pages 1-15
 26. Recombinant Production and Intein-Mediated Purification of an Antimicrobial Peptide, BR2. Shafiee, F., Minaiyan, G., Moazen, F., **Jahanian-Najafabadi, A**. *International Journal of Peptide Research and Therapeutics*. Volume 23, Issue 4, 1 December 2017, Pages 501-507

27. Artificial Blood Substitutes: First Steps on the Long Route to Clinical Utility. Samira Moradi, **Ali Jahanian-Najafabadi** and Mehryar Habibi Roudkenar. *Clinical Medicine Insights: Blood Disorders* 2016;9 33-41
28. Production and evaluation of cytotoxic effects of DT386-BR2 fusion protein as a novel anti-cancer agent. Shafiee F, Rabbani M, **Jahanian-Najafabadi A.** *J Microbiol Methods.* 2016 Nov;130:100-105
29. Expression and purification of toxic anti-breast cancer p28-NRC chimeric protein. Soleimani M, Mirmohammad-Sadeghi H, Sadeghi-Aliabadi H, **Jahanian-Najafabadi A.** *Adv Biomed Res.* 2016 Apr 19;5:70.
30. Luteinizing hormone-releasing hormone targeted poly(methyl vinyl ether maleic acid) nanoparticles for doxorubicin delivery to MCF-7 breast cancer cells. Varshosaz, J., **Jahanian-Najafabadi, A.**, Ghazzavi, J. *IET Nanobiotechnology*, Volume 10, Issue 4, Pages 206-21
31. Targeted Delivery of Docetaxel by Use of Transferrin/Poly(allylamine hydrochloride)-functionalized Graphene Oxide Nanocarrier. Nasrollahi, F., Varshosaz, J., Khodadadi, A.A., Lim, S., **Jahanian-Najafabadi, A.** *ACS Applied Materials and Interfaces*, Volume 8, Issue 21, Pages 13282-13293
32. Theoretical design of a new chimeric protein for the treatment of breast cancer. Soleimani, M., Mahnam, K., Mirmohammad-Sadeghi, H., Sadeghi-Aliabadi, H., **Jahanian-Najafabadi, A.** *Research in Pharmaceutical Sciences*, Volume 11, Issue 3, 2016, Pages 187-199
33. Adenovirus-mediated over-expression of Nrf2 within mesenchymal stem cells (MSCs) protected rats against acute kidney injury. Mohammadzadeh-Vardin, M.a, Roudkenar, M.H.b , **Jahanian-Najafabadi, A.** *Advanced Pharmaceutical Bulletin*, Volume 5, Issue 2, 2015, Pages 201-20
34. In vitro augmentation of mesenchymal stem cells viability in stressful microenvironments: In vitro augmentation of mesenchymal stem cells viability. Amiri F, **Jahanian-Najafabadi A**, Roudkenar MH. *Cell Stress Chaperones.* 2015 Mar;20(2):237-51.
35. Antigenicity and immunogenicity of fused B-subunit of heat labile toxin of Escherichia coli and colonization factor antigen I polypeptides. Savar NS, Dashti A, Darzi Eslam E, **Jahanian-Najafabadi A**, Jafari A. *J Microbiol Methods.* 2014 Nov;106:40-6.
36. Adenovirus-mediated over-expression of Nrf2 within mesenchymal stem cells (MSCs) protected rats against acute kidney injury. Mohammadzadeh-Vardin, M., Roudkenar, M.H., **Jahanian-Najafabadi, A.** *Adv. Pharm. Bulletin.* 2015; 5 (2), pp. 201-208.
37. Co-culture of bone marrow-derived mesenchymal stem cells overexpressing lipocalin 2 with HK-2 and HEK293 cells protects the kidney cells against cisplatin-induced injury. Halabian R, Roudkenar MH, **Jahanian-Najafabadi A**, Hosseini KM, Tehrani HA. *Cell Biol Int.* 2015 Feb;39(2):152-63.

38. Molecular cloning of the capsular antigen F1 of *Yersinia pestis* in pBAD/gIII plasmid. **Jahanian-Najafabadi, A.**, Soleimani, M., Azadmanesh, K., Mostafavi, E., Majidzadeh-A, K. Res. Pharm. Sci. 2015; 10 (1), pp. 91-96
39. Recombinant human lipocalin 2 acts as an antibacterial agent to prevent platelet contamination. Bakhshandeh Z, Halabian R, Imani-Fooladi AA, **Jahanian-Najafabadi A**, Jalili MA, Roudkenar MH. Hematology. 2014 Dec;19(8):487-92.
40. In silico and In vivo studies of truncated forms of flagellin (FliC) of enteroaggregative *Escherichia coli* fused to FimH from uropathogenic *Escherichia coli* as a vaccine candidate against urinary tract infections. Savar NS, **Jahanian-Najafabadi A**, Mahdavi M, Shokrgozar MA, Jafari A, Bouzari S. J Biotechnol. 2014 Apr 10;175:31-7.
41. Induction of multipotency in umbilical cord-derived mesenchymal stem cells cultivated under suspension conditions. Amiri F, Halabian R, Salimian M, Shokrgozar MA, Soleimani M, **Jahanian-Najafabadi A**, Roudkenar MH. Cell Stress Chaperones. 2014 Sep;19(5):657-66.
42. Lipocalin 2 decreases senescence of bone marrow-derived mesenchymal stem cells under sub-lethal doses of oxidative stress. Bahmani B, Roudkenar MH, Halabian R, **Jahanian-Najafabadi A**, Amiri F, Jalili MA. Cell Stress Chaperones. 2014 Sep;19(5):685-93.
43. In silico and in vitro study of truncated forms of flagellin (FliC) of enteroaggregative *Escherichia coli* (EAEC), Savar NS, Sardari S, **Jahanian-Najafabadi A** and Bouzari S. Mol. Inf. 2013, 32, 707 – 716.
44. Lipocalin-2 mediated up-regulation of various antioxidants and growth factors protects bone-marrow derived mesenchymal stem cells against unfavorable microenvironments, Raheleh Halabian, Hossein A. Tehrani, **Ali Jahanian-Najafabadi**, Mehryar Habibi Roudkenar. Cell Stress Chaperones. 2013 Nov;18(6):785-800.
45. Adenovirus-mediated over-expression of the Nrf2 protein within MSCs protected rats against acute kidney injury, Mohammadzadeh M, Habibi Roudkenar M, **Ali Jahanian-Najafabadi**. Adv Pharm Bull. 2015 Jun; 5(2):201-8.
46. HIF-1 α confers resistance to induced stress in bone marrow-derived mesenchymal stem cells, Ali Asghar Kiani, Ahmad Kazemi, Rahele Halabian, Mahshid ohammadipour, **Ali Jahanian-Najafabadi**, Mehryar Habibi Roudkenar. Arch. Med. Res., 2013. 44 (2013) 185-193
47. Expression of the recombinant plasminogen activator (reteplase) by a non-lytic insect cell expression system, S Aflakiyan, H Mir Mohammad Sadeghi, MA Shokrgozar, M Rabbani, S Bouzari, **A Jahnian-Najafabadi**, Research in Pharmaceutical Sciences 2013; 8(1): 9-15.
48. Isolation, Cloning and High- Level Expression of Neutrophil Gelatinase-Associated Lipocalin Lipocalin2 by Baculovirus Expression System through Gateway Technology. Mahdi Rouhbakhsh, Raheleh Halabian, Nasser Masroori , Mahshid Mohammadi Pour,

- Parisa Bahmani, Amaneh Mohammadi Roushandeh, **Ali Jahanian-Najafabadi**, Mehryar Habibi Roudkenar. *Iranian Journal of Basic Medical Sciences*. 2012; 3(56): 845-852.
49. Optimization of the Expression of Genes Encoding Poly (3-hydroxyalkanoate) Synthase from *Pseudomonas aeruginosa* PTCC 1310 in *Escherichia coli*. Daryoush Abedi, Maryam Beheshti, **Ali Jahanian-Najafabadi**, Hamid Mir Mohammad Sadeghi and Vajihe Akbari. *Avicenna J Med Biotech* 2012; 4(1): 47-51.
 50. Attempts to Express the A1-GMCSF Immunotoxin in the Baculovirus Expression Vector System. **Ali Jahanian-Najafabadi**, Saeid Bouzari, Mana Oloomi, Mehryar Habibi Roudkenar, and Lorenz M. Mayr. *Biosci, Biotechnol, Biochem*. 2012. 76(4).
 51. Assessment of selective toxicity of insect cell expressed recombinant A1-GMCSF protein toward GMCSF receptor bearing tumor cells. **A. Jahanian-Najafabadi**, S. Bouzari, M. Oloomi, M. Habibi Roudkenar, M.A. Shokrgozar. *Research in Pharmaceutical Sciences*, August 2012; 7(3)
 52. HESA-A Exerts Its Cytoprotective Effects through Scavenging of Free Radicals: An in Vitro Study. Mehryar Habibi Roudkenar, Parisa Bahmani, Raheleh Halabian, Amaneh Mohammadi Roushandeh, **Ali Jahanian-Najafabadi**, Mohammad Ali Shokrgozar. *Iran J Med Sci* 2012; 37(1): 47-53.
 53. Nrf-2 overexpression in mesenchymal stem cells reduces oxidative stress-induced apoptosis and cytotoxicity. Mohammad Mohammadzadeh, Raheleh Halabian, Ahmad Gharehbaghian, Naser Amirizadeh, **Ali Jahanian-Najafabadi**, Amaneh Mohammadi Roushandeh and Mehryar Habibi Roudkenar. *Cell Stress and Chaperones*, 2012 Sep;17(5):553-65.
 54. Effects of polygonum aviculare herbal extract on proliferation and apoptotic gene expression of MCF-7. Habibi Roudkenar M., Mohammadi Roushandeh A., Delazar A., Halabian R., Soleimani Rad J., Mehdipour A. Bagheri M., **Jahanian-Najafabadi A.** *DARU*, 2011;19(5) : 326-331.
 55. Inhibition of silibinin on migration and adhesion capacity of human highly metastatic breast cancer cell line, MDA-MB-231, by evaluation of β 1-integrin and downstream molecules, Cdc42, Raf-1 and D4GDI. Mohadeseh Dastpeyman, Nasrin Motamed, Kayhan Azadmanesh, Ehsan Mostafavi, Vahid Kia, **Ali Jahanian-Najafabadi**, Mohammad Ali Shokrgozar, *Medical Oncology*, 2012 Dec;29(4):2512-8.
 56. The Expression of Heme Oxygenase-1 in Human-Derived Cancer Cell Lines. P. Bahmani, G.H. Hassanshahi, R. Halabian, A. Mohammadi Roushandeh, **A. Jahanian-Najafabadi**, M. Habibi Roudkenar. *Iran J Med Sci*. December 2011; Vol 36 No 4.
 57. Adenovirus-mediated expression of the HO-1 protein within MSCs decreased cytotoxicity and inhibited apoptosis induced by oxidative stresses, Pejman Hamedi-Asl, Raheleh Halabian, Parisa Bahmani, Mahshid Mohammadipour, Mohammad Mohammadzadeh, Amaneh Mohammadi Roushandeh, **Ali Jahanian-Najafabadi**, Yoshikazu Kuwahara & Mehryar Habibi Roudkenar. *Cell Stress and Chaperones*, 2012 Mar;17(2):181-90.

58. Genetically engineered mesenchymal stem cells stably expressing green fluorescent protein. Raheleh Halabian, Mohamad Hosein Mohammadi, Mohammad Salimi, Maryam Amani, Amaneh Mohammadi Roushande, Mahnaz Aghaipoor, Nasser Amirizadeh, Majid Ebrahimi, **Ali Jahanian Najafabadi**, Mehryar Habibi Roudkenar. Iranian Journal of Basic Medical Sciences. Vol. 13, No. 2, Spring 2010, 24-30
59. High-level expression of functional recombinant human coagulation factor VII in insect cells. Masroori N, Halabian R, Mohammadipour M, Roushandeh AM, Rouhbakhsh M, **Najafabadi AJ**, Fathabad ME, Salimi M, Shokrgozar MA, Roudkenar MH. Biotechnol let. 2010 Mar 7.
60. Lipocalin 2 regulation by thermal stresses: Protective role of Lcn2/NGAL against cold and heat stresses. Mehryar Habibi Roudkenar, Raheleh Halabian, Amaneh Mohammadi Roushandeh, Mohammad Reza Nourani, Nasser Masroori, Majid Ebrahimi, Mahin Nikogoftar, Mehdi Rouhbakhsh, Parisa Bahmani, **Ali Jahanian Najafabadi**, Mohammad Ali Shokrgozar. Experimental Cell Research 2009; 315: 3140-3151
61. Expression and purification of recombinant human coagulation Factor VII fused to His-Tag through Gateway technology. Raheleh Halabian, Mahdi Edalati Fathabad, Nasser Masroori, Amaneh Mohammadi Roushandeh, Sasan Saki, Nasser Amirizadeh, **Ali Jahanian Najafabadi**, Ahmad Gharehbaghian, Mehryar Habibi Roudkenar. Blood Transfusion 2009; 7: 305-12.
62. Establishment of a cell line expressing recombinant factor VII and its subsequent conversion to active form FVIIa through hepsin by genetic engineering method. Halabian R, Roudkenar MH, Esmaeili NS, Masroori N, Roushandeh AM, **Najafabadi AJ**. Vox Sang. 2009 May; 96(4):309-15. Epub 2009 Jan 19.
63. Identification of an isolate of *Pseudomonas aeruginosa* deposited in PTCC as a PHA producer strain: Comparison of three different bacterial genomic DNA extraction methods. Hamid Mir Mohammad Sadeghi , **Ali Jahanian Najafabadi**, Daryoush Abedi, Abbas Jafarian Dehkordi. Journal of Biological Sciences, 2008. 8(4): 826-830.
64. Cloning and partial sequencing of *phaC1* and *phaC2* genes encoding Poly(3-hydroxyalkanoate) synthases from *Pseudomonas aeruginosa* PTCC 1310. Daryoush Abedi, **Ali Jahanian Najafabadi**, Hamid Mirmohammad Sadeghi, Sadeq Vallian. Biotechnology 2007. 6(4): 497-504.

Abstracts:

- **In vitro and in vivo cytolethal and antitumor effects of a novel fusion protein targeting IL-24 toward breast cancer cells.** A Jahanian-Najafabadi, R Ghavimi, V Akbari. Targeted Anticancer Therapy 2020, March 2-5, Paris, France.
- **Optimization of recombinant proteins production in Escherichia coli using a two-step chaperones-based system.** Jahanian-Najafanbadi, A, Sadeghian Rizi, T, Ebrahimi, A. SynBio4. 27-28 May 2019. Waterloo, Canada.

- **Introduction of a novel cancer cell targeted fusion protein: DT386-BR2.** A Jahanian-Najafabadi, F Shafiee, M Rabbani. Targeted Anticancer Therapy 2018, 5-7 March 2018, Paris, France.
- **Expression of reteplase by a non-viral insect cell expression system.** S. Aflakiyan, H. Mir Mohammad Sadeghi, M. Shokrgozar, M. Rabbani, S. Bouzari, A. Jahanian-Najafabadi. 13th Iranian Pharmaceutical Sciences Congress, 2012, Isfahan, Iran.
- **Production of recombinant A254-GMCSF immunotoxin by a non-lytic insect cell expression and evaluation of its cytotoxicity by in vitro studies.** A. Jahanian-Najafabadi, S. Bouzari, M. Oloomi, M. Habibi Roudkenar, M. Shokrgozar. 13th Iranian Pharmaceutical Sciences Congress, 2012, Isfahan, Iran.

Positions:

- Head of General Research Lab, Isfahan University of Medical Sciences and Health Services, Isfahan, Iran. Oct. 2014 to 2017.
- Deputy Dean of Research, Faculty of Pharmacy, Isfahan University of Medical Sciences and Health Services, Isfahan, Iran. Jan. 2014 to Feb 2018.
- Head of Pharmaceutical Biotechnology Department, Faculty of Pharmacy, Isfahan University of Medical Sciences and Health Services, Sep. 2013 to Mar 2018

Teaching Experiences

- Molecular Biology and Genetics
- Pharmaceutical Biotechnology: Monoclonal Antibody, Growth Factors and Cytokines, Therapeutic Enzymes and Protein Hormones, Nucleic acids and Cell Based Therapeutics
- Microbial Control of Pharmaceutical Products
- Quality Control of Biopharmaceuticals
- Genetic Engineering
- Vaccine production and cancer vaccines
- Bioprocess engineering: Downstream processing
- Baculovirus and insect cell expression systems
- Bioinformatics

Laboratory skills:

- Molecular cloning related techniques
- Cell culture
- *E. coli* expression system
- Baculovirus expression system
- Non-lytic insect cell expression system
- Mammalian Expression system
- Real Time/RT-PCR
- Laboratory Animal handling
- Production and purification of Rabbit polyclonal antibodies